Rein Therapeutics (NASDAQ:RNTX) Stock Rating Lowered by Wall Street Zen

Rein Therapeutics (NASDAQ:RNTX) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

RNTX has been the topic of a number of other reports. HC Wainwright began coverage on Rein Therapeutics in a research note on Monday, September 22nd. They issued a “buy” rating and a $10.00 price objective on the stock. Brookline Capital Management raised Rein Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rein Therapeutics in a research note on Wednesday, October 8th. Finally, Loop Capital set a $6.00 target price on Rein Therapeutics in a research report on Monday, November 3rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Rein Therapeutics presently has a consensus rating of “Hold” and an average price target of $8.00.

Rein Therapeutics Stock Performance

Shares of RNTX opened at $1.48 on Friday. The business’s fifty day moving average is $1.42 and its 200-day moving average is $1.40. The firm has a market cap of $38.91 million, a price-to-earnings ratio of -0.56 and a beta of 1.27. Rein Therapeutics has a 52-week low of $1.04 and a 52-week high of $3.50.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.03. As a group, research analysts forecast that Rein Therapeutics will post -1.56 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Voss Capital, Lp purchased 178,392 shares of the firm’s stock in a transaction dated Tuesday, October 28th. The shares were purchased at an average cost of $1.39 per share, for a total transaction of $247,964.88. Following the completion of the transaction, the insider directly owned 500,000 shares in the company, valued at approximately $695,000. This represents a 55.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders bought 410,233 shares of company stock worth $550,563. 5.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Senvest Management LLC bought a new position in Rein Therapeutics in the 2nd quarter worth about $323,000. Sigma Planning Corp bought a new stake in Rein Therapeutics in the second quarter valued at approximately $387,000. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Rein Therapeutics in the second quarter worth about $716,000. Chicago Partners Investment Group LLC purchased a new position in Rein Therapeutics during the 2nd quarter valued at $64,000. Finally, Exencial Wealth Advisors LLC bought a new position in shares of Rein Therapeutics in the 2nd quarter worth approximately $43,000. Institutional investors own 90.89% of the company’s stock.

About Rein Therapeutics

Rein Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers.